BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
5.14
-0.46 (-8.21%)
Aug 14, 2025, 1:58 PM - Market open
BioXcel Therapeutics Stock Forecast
BTAI's stock price has decreased by -51.89% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for BioXcel Therapeutics stock ranges from a low of $4.00 to a high of $80. The average analyst price target of $39.5 forecasts a 668.48% increase in the stock price over the next year.
Price Target: $39.50 (+668.48%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jul 15, 2025.
Analyst Ratings
The average analyst rating for BioXcel Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LUCID CAPITAL MARKETS | LUCID CAPITAL MARKETS | Strong Buy Reiterates $66 | Strong Buy | Reiterates | $66 | +1,184.05% | Jul 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3 → $8 | Strong Buy | Maintains | $3 → $8 | +55.64% | Jun 23, 2025 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $65 | Strong Buy | Initiates | $65 | +1,164.59% | Mar 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $80 → $48 | Strong Buy | Maintains | $80 → $48 | +833.85% | Jan 30, 2025 |
| B of A Securities | B of A Securities | Strong Buy → Sell Downgrades $112 → $4 | Strong Buy → Sell | Downgrades | $112 → $4 | -22.18% | Jan 7, 2025 |
Financial Forecast
Revenue This Year
1.44M
from 2.27M
Decreased by -36.45%
Revenue Next Year
6.17M
from 1.44M
Increased by 328.13%
EPS This Year
-7.01
from -23.51
EPS Next Year
-5.91
from -7.01
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.5M | 17.4M | 125.2M | ||
| Avg | 1.4M | 6.2M | 76.5M | ||
| Low | 658,560 | 658,560 | 30.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 8.9% | 1,110.4% | 1,931.5% | ||
| Avg | -36.5% | 328.1% | 1,140.7% | ||
| Low | -70.9% | -54.3% | 388.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.37 | -2.12 | 3.84 | ||
| Avg | -7.01 | -5.91 | 0.68 | ||
| Low | -8.99 | -11.63 | -2.28 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.